双作用抗菌药:抗菌化疗新实现的概念

Roy Cleeland, Harry Albrecht, George Beskid, Kakong Chan, James Christenson, Nafsika Georgopapadakou, Dennis Keith, David Pruess, Edwina Squires, Chung Chen Wei, Manfred Weigele
{"title":"双作用抗菌药:抗菌化疗新实现的概念","authors":"Roy Cleeland,&nbsp;Harry Albrecht,&nbsp;George Beskid,&nbsp;Kakong Chan,&nbsp;James Christenson,&nbsp;Nafsika Georgopapadakou,&nbsp;Dennis Keith,&nbsp;David Pruess,&nbsp;Edwina Squires,&nbsp;Chung Chen Wei,&nbsp;Manfred Weigele","doi":"10.1016/0738-1751(89)90014-2","DOIUrl":null,"url":null,"abstract":"<div><p>Ro 23-9424 represents the culmination of an idea put forth by O'Callaghan et al<sup>4</sup> in 1976. They proposed that a cephalosporin could act as a carrier for a second antibacterial with the total molecule functioning as a single antibacterial until separated by opening of the ß-lactam ring by a ß-lactamase or, as we now know, the target penicillin-sensitive enzymes. It is important to note that in spite of the ester linkage, hydrolysis of Ro 23-9424 in animals to the components is minimal and the elimination kinetics are those of a single molecule with a pharmacokinetic profile of the cephalosporin component. The results of our preliminary toxicology studies in rats and dogs also suggest that this compound will have a safety profile similar to that of the cephalosporin component. This would allow parenteral administration of the quinolone component, fleroxacin, at a much higher dosage than is possible with the free quinolone.</p><p>Ro 23-9424 represents the first of a new class of antibacterials. The major constraint in designing new compounds within this class will only be the ingenuity of the pharmaceutical chemist.</p></div>","PeriodicalId":100101,"journal":{"name":"Antimicrobic Newsletter","volume":"6 8","pages":"Pages 61-65"},"PeriodicalIF":0.0000,"publicationDate":"1989-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0738-1751(89)90014-2","citationCount":"1","resultStr":"{\"title\":\"Dual-action antibacterials: A concept newly realized for antibacterial chemotherapy\",\"authors\":\"Roy Cleeland,&nbsp;Harry Albrecht,&nbsp;George Beskid,&nbsp;Kakong Chan,&nbsp;James Christenson,&nbsp;Nafsika Georgopapadakou,&nbsp;Dennis Keith,&nbsp;David Pruess,&nbsp;Edwina Squires,&nbsp;Chung Chen Wei,&nbsp;Manfred Weigele\",\"doi\":\"10.1016/0738-1751(89)90014-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ro 23-9424 represents the culmination of an idea put forth by O'Callaghan et al<sup>4</sup> in 1976. They proposed that a cephalosporin could act as a carrier for a second antibacterial with the total molecule functioning as a single antibacterial until separated by opening of the ß-lactam ring by a ß-lactamase or, as we now know, the target penicillin-sensitive enzymes. It is important to note that in spite of the ester linkage, hydrolysis of Ro 23-9424 in animals to the components is minimal and the elimination kinetics are those of a single molecule with a pharmacokinetic profile of the cephalosporin component. The results of our preliminary toxicology studies in rats and dogs also suggest that this compound will have a safety profile similar to that of the cephalosporin component. This would allow parenteral administration of the quinolone component, fleroxacin, at a much higher dosage than is possible with the free quinolone.</p><p>Ro 23-9424 represents the first of a new class of antibacterials. The major constraint in designing new compounds within this class will only be the ingenuity of the pharmaceutical chemist.</p></div>\",\"PeriodicalId\":100101,\"journal\":{\"name\":\"Antimicrobic Newsletter\",\"volume\":\"6 8\",\"pages\":\"Pages 61-65\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1989-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0738-1751(89)90014-2\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobic Newsletter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0738175189900142\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobic Newsletter","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0738175189900142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

Ro 23-9424代表了O'Callaghan等人在1976年提出的一个想法的高潮。他们提出,头孢菌素可以作为第二种抗菌药物的载体,整个分子作为单一抗菌药物发挥作用,直到被ß-内酰胺酶打开ß-内酰胺环,或者,正如我们现在所知道的,目标青霉素敏感酶分开。值得注意的是,尽管存在酯链,但ro23 -9424在动物体内对这些成分的水解是最小的,其消除动力学是具有头孢菌素成分药代动力学特征的单分子。我们在大鼠和狗身上进行的初步毒理学研究结果也表明,这种化合物将具有与头孢菌素成分相似的安全性。这将允许静脉注射喹诺酮成分氟沙星,其剂量比使用游离喹诺酮可能要高得多。Ro 23-9424是一类新型抗菌药物中的第一种。在这类化合物中设计新化合物的主要限制只在于药物化学家的独创性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Dual-action antibacterials: A concept newly realized for antibacterial chemotherapy

Ro 23-9424 represents the culmination of an idea put forth by O'Callaghan et al4 in 1976. They proposed that a cephalosporin could act as a carrier for a second antibacterial with the total molecule functioning as a single antibacterial until separated by opening of the ß-lactam ring by a ß-lactamase or, as we now know, the target penicillin-sensitive enzymes. It is important to note that in spite of the ester linkage, hydrolysis of Ro 23-9424 in animals to the components is minimal and the elimination kinetics are those of a single molecule with a pharmacokinetic profile of the cephalosporin component. The results of our preliminary toxicology studies in rats and dogs also suggest that this compound will have a safety profile similar to that of the cephalosporin component. This would allow parenteral administration of the quinolone component, fleroxacin, at a much higher dosage than is possible with the free quinolone.

Ro 23-9424 represents the first of a new class of antibacterials. The major constraint in designing new compounds within this class will only be the ingenuity of the pharmaceutical chemist.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The fourth-generation cephalosporins: Antimicrobial activity and spectrum definitions using cefpirome as an example Editor's Note Haemophilus test medium (HTM) susceptibility methods: Results of evaluations of reproducibility, stability, and medium quality Historical overview of the cephalosporin spectrum: Four generations of structural evolution Index to volume 8
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1